Company intelligence / Profile preview

MabCare Therapeutics

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

MTX-13 (DAY301), an ADC targeting PTK7, demonstrated anti-tumor activity in a broad range of solid tumors in preclinical studies and was cleared by FDA for a Phase 1 study; clinical dosing to begin by end of 2024 or early 2025[2][3][4].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateAntibody
Industry: Biotech

Partnerships

Day One Biopharmaceuticals (exclusive licensing of MTX-13/DAY301 ex-Greater China)[1][2][3][4][6][8]

Beyond the preview

Go deeper on MabCare Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MabCare Therapeutics.

Explore the full profile